Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with lung cancer: results from an interim analysis of the non-interventional study NADIR.

Potthoff, K., Lück, A., Frost, N., Losem, C., Weide, R., Schulz, H., 2016.

Oncol Res Treat 39 (suppl3)(P949), 292. doi:10.1159/000449050

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
NADIR
2016
Patient-reported outcomes of 905 patients with breast cancer two years after start of curative systemic treatment.

Marschner, N., Trarbach, T., Dörfel, S., Meyer, D., Müller-Hagen, S., Zaiss, M., Boller, E., Kruggel, L., 2016.

Oncol Res Treat 39 (suppl 5)(V385), 116. doi:10.1159/000449050

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TMK
2016
Overall survival of 4865 patients with metastatic solid tumours treated in German routine practice – combined results from four prospective, multicentre cohort studies.

Marschner, N., Potthoff, K., Schnell, R., Tesch, H., Zahn, M.-O., Hegewisch-Becker, S., Jänicke, M., 2016.

Oncol Res Treat 39 (suppl.3)(V174), 43. doi:10.1159/000449050

Abstract

Indikation: Other, Sonstige / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
Indikationsübergreifend
2016
Efficacy and safety of nab-paclitaxel in patients with metastatic breast cancer: Final results of the non-interventional study NABUCCO.

Marschner, N., Potthoff, K., Salat, C., Söling, U., Hansen, R., Grebhardt, S., Harde, Nusch, A., 2016.

Oncol Res Treat 39 (suppl3)(P598), 183. doi:10.1159/000449050

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
NABUCCO
2016
1st -line treatment of patients with mantle cell lymphoma: Treatment reality and first outcome data from the German prospective TLN Registry.

Knauf, W., Bertram, Fietz, T., Kirste, T., Grugel, R., Schnitzler, Abenhardt, W., 2016.

Oncol Res Treat 39 (suppl 3)(V364), 120. doi:10.1159/000449050

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLN
2016
Parenteral nutrition support for patients with advanced pancreatic cancer – interim results from the sub-project „PaNut“ of the Pancreatic Cancer Registry (TPK).

Hegewisch-Becker, S., Wolf, T., Reiser, M., Scheiner-Sparna, R., Hamm, D., Marschner, N., 2016.

Oncol Res Treat 39 (suppl3)(P869), 261. doi:10.1159/000449050

Abstract

Download

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TPK
2016
Patient-reported outcomes of patients with advanced or metastatic pancreatic cancer in German outpatient centres – first data from the sub-project PanLife of the clinical Pancreatic Cancer Registry (TPK).

Hegewisch-Becker, S., Wolf, T., Aldaoud, A., Scheiner-Sparna, R., Hamm, D., Marschner, N., 2016.

Oncol Res Treat 39 (suppl3)(V1026), 318 doi:10.1159/000449050

Abstract

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TPK
2016
Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): A prospective German registry in stage IV NSCLC AIO-TRK-0315.

Griesinger, F., Eberhardt, W.E., Marschner, N., Jänicke, M., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Sebastian, M., Thomas, M., 2016.

Oncol Res Treat 39 (suppl3)(P295), 90. doi:10.1159/000449050

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2016
Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with Non-Hodgkin-Lymphoma (NHL): results from an interim analysis of the non-interventional study NADIR.

Fietz, T., Wolff, T., Schulz, H., Sandner, R., Reichert, D., Hurtz, H.-J., Müller, J., Grebhardt, S., 2016.

Oncol Res Treat, DGHO-Jahrestagung (Leipzig) 39 (suppl3)(P950), 292. doi:10.1159/000449050

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
NADIR
2016
Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with breast cancer: results from an interim analysis of the non-interventional study NADIR.

Fietz, T., Kurbacher, C.M., Trarbach, T., Salat, C., Rezai, M., Lorenz, A., Niemeier, B., 2016.

Oncol Res Treat 39 (suppl3)(P952), 293. doi:10.1159/000449050

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
NADIR
2016